HRP20210085T1 - Pripravci i postupci za liječenje disfunkcije meibomske žlijezde - Google Patents
Pripravci i postupci za liječenje disfunkcije meibomske žlijezde Download PDFInfo
- Publication number
- HRP20210085T1 HRP20210085T1 HRP20210085TT HRP20210085T HRP20210085T1 HR P20210085 T1 HRP20210085 T1 HR P20210085T1 HR P20210085T T HRP20210085T T HR P20210085TT HR P20210085 T HRP20210085 T HR P20210085T HR P20210085 T1 HRP20210085 T1 HR P20210085T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- topical application
- meibomian gland
- concentration
- Prior art date
Links
- 206010065062 Meibomian gland dysfunction Diseases 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 8
- 230000000699 topical effect Effects 0.000 claims 8
- 239000003410 keratolytic agent Substances 0.000 claims 5
- 210000004175 meibomian gland Anatomy 0.000 claims 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 4
- 229960004889 salicylic acid Drugs 0.000 claims 4
- 102000011782 Keratins Human genes 0.000 claims 2
- 108010076876 Keratins Proteins 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 229910000338 selenium disulfide Inorganic materials 0.000 claims 2
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N selenium sulfide Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 claims 2
- 229960005265 selenium sulfide Drugs 0.000 claims 2
- 229940124091 Keratolytic Drugs 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 230000001530 keratinolytic effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Pripravak koji se upotrebljava u postupku liječenja disfunkcije meibomske žlijezde kod pacijenta kojemu je to potrebno, dok navedeni postupak obuhvaća topikalnu primjenu pripravka u rub očnog kapka, pri čemu pripravak obuhvaća terapeutski učinkovitu količinu najmanje jednog keratolitskog agensa u oftalmički prihvatljivom nosaču, gdje je keratolitski agens odabran od selen disulfida u koncentraciji od 0,1 % do 10 % ili salicilne kiseline u koncentraciji od 0,1 % do 30 %; te je pritom disfunkcija meibomske žlijezde naznačena time, da ima keratinsku opstrukciju terminalnog kanala meibomske žlijezde.
2. Pripravak za uporabu prema patentnom zahtjevu 1, gdje se pripravak sastoji od terapeutski učinkovite količine keratolitskog agensa u oftalmički prihvatljivom nosaču, pri čemu je keratolitski agens odabran od selen disulfida u koncentraciji od 0,1 % do 10 %, ili salicilne kiseline u koncentraciji od 0,1 % do 30 %; te je pritom disfunkcija meibomske žlijezde, naznačena time, da ima keratinsku opstrukciju terminalnog kanala meibomske žlijezde.
3. Pripravak za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da keratolitski agens je salicilna kiselina u koncentraciji od 0,1 % do 10 %.
4. Pripravak za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da keratolitski agens je salicilna kiselina u koncentraciji od 0,1 % do 6 %.
5. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da topikalna primjena je jedno davanje.
6. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da topikalna primjena je periodično davanje.
7. Pripravak za uporabu prema patentnom zahtjevu 6, naznačen time, da periodično davanje je jednom dnevno, ili dva puta dnevno.
8. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da pripravak za topikalnu primjenu je polukrut.
9. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da pripravak za topikalnu primjenu je homogen.
10. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da pripravak za topikalnu primjenu je disperzija.
11. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da pripravak za topikalnu primjenu je hidrofilan.
12. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da pripravak za topikalnu primjenu ima uljanu bazu.
13. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time, da oftalmički prihvatljiv nosač sadrži najmanje jedno oftalmički prihvatljivo pomoćno sredstvo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462065716P | 2014-10-19 | 2014-10-19 | |
US14/732,622 US9463201B2 (en) | 2014-10-19 | 2015-06-05 | Compositions and methods for the treatment of meibomian gland dysfunction |
PCT/IB2015/002164 WO2016063130A1 (en) | 2014-10-19 | 2015-10-16 | Compositions and methods for the treatment of meibomian gland dysfunction |
EP15852086.6A EP3206497B1 (en) | 2014-10-19 | 2015-10-16 | Compositions and methods for the treatment of meibomian gland dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210085T1 true HRP20210085T1 (hr) | 2021-03-05 |
Family
ID=55748155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210085TT HRP20210085T1 (hr) | 2014-10-19 | 2021-01-19 | Pripravci i postupci za liječenje disfunkcije meibomske žlijezde |
Country Status (22)
Country | Link |
---|---|
US (7) | US9463201B2 (hr) |
EP (2) | EP3831396A1 (hr) |
JP (3) | JP6799532B2 (hr) |
KR (2) | KR102350869B1 (hr) |
CN (2) | CN112972682A (hr) |
AU (2) | AU2015334586B2 (hr) |
BR (1) | BR112017007975A2 (hr) |
CA (1) | CA2964685A1 (hr) |
CY (1) | CY1123821T1 (hr) |
DK (1) | DK3206497T3 (hr) |
ES (1) | ES2848102T3 (hr) |
HR (1) | HRP20210085T1 (hr) |
HU (1) | HUE053485T2 (hr) |
IL (2) | IL251724B (hr) |
LT (1) | LT3206497T (hr) |
MX (2) | MX2017005030A (hr) |
PL (1) | PL3206497T3 (hr) |
PT (1) | PT3206497T (hr) |
RS (1) | RS61295B1 (hr) |
RU (1) | RU2730464C2 (hr) |
SI (1) | SI3206497T1 (hr) |
WO (1) | WO2016063130A1 (hr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9888839B2 (en) | 2009-04-01 | 2018-02-13 | Tearscience, Inc. | Methods and apparatuses for determining contact lens intolerance in contact lens wearer patients based on dry eye tear film characteristic analysis and dry eye symptoms |
EP2413699B1 (en) | 2009-04-01 | 2019-11-20 | Tearscience, Inc. | Ocular surface interferometry (osi) apparatus for imaging an ocular tear film |
US9642520B2 (en) | 2009-04-01 | 2017-05-09 | Tearscience, Inc. | Background reduction apparatuses and methods of ocular surface interferometry (OSI) employing polarization for imaging, processing, and/or displaying an ocular tear film |
US9339177B2 (en) | 2012-12-21 | 2016-05-17 | Tearscience, Inc. | Full-eye illumination ocular surface imaging of an ocular tear film for determining tear film thickness and/or providing ocular topography |
ES2901406T3 (es) | 2013-05-03 | 2022-03-22 | Tearscience Inc | Sistemas y métodos de iluminación de párpados para imagenología de las glándulas de Meibomio para análisis de las glándulas de Meibomio |
US9795290B2 (en) | 2013-11-15 | 2017-10-24 | Tearscience, Inc. | Ocular tear film peak detection and stabilization detection systems and methods for determining tear film layer characteristics |
US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
WO2017024032A2 (en) | 2015-08-03 | 2017-02-09 | Enb Therapeutics, Llc | Compositions and methods for treating cancers associated with etbr activation |
JP2018533622A (ja) | 2015-09-28 | 2018-11-15 | アズーラ オフサルミックス エルティーディー. | マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 |
KR102414557B1 (ko) * | 2016-04-14 | 2022-06-28 | 아주라 오프탈믹스 엘티디 | 마이봄샘 기능 이상의 치료에 사용하기 위한 이황화셀레늄 조성물 |
MA44737A (fr) | 2016-04-19 | 2021-04-07 | Azura Ophthalmics Ltd | Compositions pour le traitement de troubles liés à l'hyperkératose |
CN110719775A (zh) * | 2017-03-29 | 2020-01-21 | 阿祖拉眼科有限公司 | 用于增加睑板腺脂质分泌的药剂 |
US11951039B2 (en) | 2017-05-05 | 2024-04-09 | eyeThera LLC | Devices and methods for treating eyelids |
US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
NZ766141A (en) | 2017-12-15 | 2024-01-26 | Tarsus Pharmaceuticals Inc | Isoxazoline parasiticide formulations and methods for treating blepharitis |
MX2020007293A (es) | 2018-01-12 | 2021-01-08 | Enb Therapeutics Inc | Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr. |
WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
EP3952881A4 (en) * | 2019-04-12 | 2023-01-04 | Azura Ophthalmics Ltd. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONTACT LENS DISCOMFORT |
AU2020259997A1 (en) | 2019-04-18 | 2021-11-25 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
KR20220003555A (ko) | 2019-04-18 | 2022-01-10 | 아주라 오프탈믹스 엘티디 | 안구 장애의 치료를 위한 화합물 및 방법 |
JP2022543361A (ja) * | 2019-08-05 | 2022-10-12 | サイト サイエンシーズ, インコーポレイテッド | 撮像システムを備えた制御部 |
CA3160069A1 (en) * | 2019-11-04 | 2021-05-14 | Azura Ophthalmics Ltd. | Metered dose for disorders in or around the eye |
WO2021090058A2 (en) * | 2019-11-04 | 2021-05-14 | Azura Ophthalmics Ltd. | Metered dose for demodex and disorders related thereto |
JP2023510499A (ja) | 2020-01-10 | 2023-03-14 | アズーラ オフサルミックス エルティーディー. | 組成物および過敏症のための指示 |
WO2021191273A1 (en) | 2020-03-24 | 2021-09-30 | Hovione Scientia Limited | Compositions for use in treating meibomian gland dysfunction |
US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
AU2022296017A1 (en) * | 2021-06-24 | 2024-01-18 | Azura Ophthalmics Ltd. | Compositions and methods for vision improvement |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3236730A (en) | 1962-01-04 | 1966-02-22 | Miles Lab | Blepharitis composition comprising antiseptic, quaternary ammonium compound, keratolytic agent and a chelating compound |
US5602130A (en) | 1987-03-20 | 1997-02-11 | Allergan | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
US5645827A (en) * | 1992-09-30 | 1997-07-08 | Union Carbide Chemicals & Plastics Technology Corporation | Muco-adhesive polymers |
CN1050748C (zh) * | 1993-04-22 | 2000-03-29 | 孟丽君 | 表面麻醉涂膜剂的制备方法 |
JP2891883B2 (ja) | 1993-11-05 | 1999-05-17 | 学校法人近畿大学 | 抗白内障医薬組成物 |
WO1997020578A1 (en) | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
EP0930072A1 (en) | 1998-01-13 | 1999-07-21 | Kartar Dr. Lalvani | Vitamin and mineral containing compositions for the treatment of dry eye |
US6348508B1 (en) | 2000-04-04 | 2002-02-19 | Bausch & Lomb Incorporated | Method for treating dry eye |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
FR2832637B1 (fr) | 2001-06-07 | 2004-07-30 | Lefaix Marie Therese Droy | Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface |
SI1441734T1 (sl) | 2001-10-26 | 2007-08-31 | Angeletti P Ist Richerche Bio | Dihidropirimidin karboksamidni inhibitorji HIV-integraze |
FR2833268B1 (fr) | 2001-12-12 | 2005-07-08 | Fabre Pierre Dermo Cosmetique | Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation |
KR100564386B1 (ko) * | 2002-05-13 | 2006-03-27 | 주식회사 마이코플러스 | 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 지루치료용 약제학적 조성물 |
US8420699B1 (en) | 2002-06-19 | 2013-04-16 | Irvine L. Dubow | Composition and methods of treatment using deionized and ozonated solution |
EP2319493A3 (en) | 2002-07-23 | 2011-07-27 | Novartis AG | Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
EP2272340B1 (en) | 2002-08-19 | 2018-03-14 | Ira Sanders | Botulinum toxin |
US20040171561A1 (en) * | 2002-09-03 | 2004-09-02 | Popp Karl F. | Topical formulations for treatment of rosacea |
EP1551399A4 (en) | 2002-09-30 | 2011-01-05 | Mark A Babizhayev | METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT |
US20060188471A1 (en) * | 2002-10-31 | 2006-08-24 | Podolsky Daniel K | Methods of treating epithelial lesions |
GB0225795D0 (en) | 2002-11-05 | 2002-12-11 | Guillon Michael | Wipes |
US20070269537A1 (en) * | 2003-02-10 | 2007-11-22 | Bioderm Research | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System |
GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
WO2005067892A1 (en) | 2004-01-10 | 2005-07-28 | Biolipid, Inc. | Lipid compositions and methods of use |
GB0404693D0 (en) | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
US20050197614A1 (en) | 2004-03-04 | 2005-09-08 | Wilson Pritchard | Occlusive biomedical devices, punctum plugs, and methods of use thereof |
US8455016B2 (en) | 2004-03-12 | 2013-06-04 | Melbj Holdings, Llc | Treatment for meibomian gland dysfunction or obstruction |
US20050202097A1 (en) | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
EP1621191A1 (en) | 2004-07-29 | 2006-02-01 | Werner Bollag | Treatment of inflammatory diseases by RXR Antagonists |
WO2006119174A1 (en) * | 2005-04-30 | 2006-11-09 | Ocular Surface Center, P.A. | Method for treating ocular demodex |
AU2006260184B2 (en) | 2005-06-22 | 2011-05-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Prophylactic or therapeutic agent for corneal/conjunctival disease |
WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
US7981095B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
US8915253B2 (en) | 2005-07-18 | 2014-12-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
US20070166402A1 (en) | 2005-12-12 | 2007-07-19 | Friedlaender Mitchell H | Compositions, methods and kits for removing debris from an ocular area |
RU2314102C1 (ru) * | 2006-04-07 | 2008-01-10 | Федеральное государственное учреждение "МОСКОВСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ имени ГЕЛЬМГОЛЬЦА ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" | Способ комплексного лечения дисфункции мейбомиевых желез |
EP2021514A2 (en) | 2006-05-10 | 2009-02-11 | Dxterity Diagnostics | Detection of nucleic acid targets using chemically reactive oligonucleotide probes |
NZ583333A (en) | 2006-05-31 | 2011-06-30 | Medihoney Pty Ltd | Medicinal Compositions Containing Honey |
US20080021068A1 (en) * | 2006-07-24 | 2008-01-24 | Akorn, Inc. | Aqueous gel formulation and method for inducing topical anesthesia |
US20090123527A1 (en) * | 2006-07-24 | 2009-05-14 | Akorn, Inc. | Method of inducing topical anesthesia and transdermal patch |
WO2008027069A1 (en) * | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction employing fluid |
US8249695B2 (en) | 2006-09-29 | 2012-08-21 | Tearscience, Inc. | Meibomian gland imaging |
US8090426B2 (en) | 2006-10-27 | 2012-01-03 | Felder Robin A | Microelectronic biosensor plug |
CA2668414C (en) * | 2006-11-03 | 2015-02-10 | Qlt Inc. | Methods of treating dermatological disorders or conditions |
JP4987078B2 (ja) | 2006-11-30 | 2012-07-25 | 株式会社メニコン | 眼科用組成物 |
JP2010520210A (ja) * | 2007-02-28 | 2010-06-10 | アーシエックス セラピューティックス, インコーポレイテッド | マイボーム腺分泌を正常化するための方法および組成物 |
US8128968B2 (en) | 2007-08-29 | 2012-03-06 | Tissuetech, Inc. | Compositions and methods for treating Demodex infestations |
US8435544B2 (en) | 2007-10-08 | 2013-05-07 | Lux Biosciences, Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors |
CA2719453A1 (en) | 2008-03-26 | 2009-10-01 | Eric Donnenfeld | Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics |
EP2276471B1 (en) | 2008-04-30 | 2018-08-08 | Mati Therapeutics Inc. | Composite lacrimal insert and related methods |
KR20110031973A (ko) | 2008-07-10 | 2011-03-29 | 알러간, 인코포레이티드 | 눈 및 피부의 질환 및 상태를 치료하기 위한 사이클로스포린 유도체 |
WO2010033800A2 (en) | 2008-09-19 | 2010-03-25 | Alacrity Biosciences, Inc. | Tetracycline stabilizing formulations |
WO2010127227A1 (en) | 2009-05-01 | 2010-11-04 | Advanced Vision Research, Inc. | Cleanser compositions and methods for using the same |
WO2011006079A2 (en) | 2009-07-10 | 2011-01-13 | Lyotropoic Therapeutics, Inc. | Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using |
CN101612161A (zh) * | 2009-08-07 | 2009-12-30 | 魏谠全 | 一种眼药组合物及其制剂 |
CN102038953B (zh) * | 2009-10-14 | 2012-07-18 | 上海昊海生物科技股份有限公司 | 一种眼科手术前局部麻醉用组合物及其制备方法和用途 |
RS59483B1 (sr) | 2009-10-30 | 2019-12-31 | Intratus Inc | Postupci i kompozicije za neprekidno oslobađanje lekova |
CA2780453A1 (en) | 2009-12-02 | 2011-06-09 | Bridge Pharma, Inc. | Treating xerophthalmia with compounds increasing meibomian gland secretion |
EP2552349A4 (en) * | 2010-03-31 | 2017-12-06 | Ocuject, LLC | Device and method for intraocular drug delivery |
US8304840B2 (en) | 2010-07-29 | 2012-11-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Spacer structures of a semiconductor device |
US20120093876A1 (en) | 2010-10-13 | 2012-04-19 | Aciex, Inc. | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions |
CA2812164A1 (en) | 2010-11-08 | 2012-05-18 | Healor Ltd. | Buffered ophthalmic compositions and methods of use thereof |
US20140031341A1 (en) * | 2010-12-22 | 2014-01-30 | Universitat Munster | Modulators and methods for the treatment of rosacea |
US20130274214A1 (en) | 2010-12-29 | 2013-10-17 | Inspire Pharmaceuticals, Inc. | Method for treating blepharitis |
US20130281390A1 (en) | 2010-12-29 | 2013-10-24 | Kurt E. Brubaker | Method for treating dry eye |
WO2012092320A2 (en) | 2010-12-29 | 2012-07-05 | Nichamin Louis D | Eye treatment |
ES2672238T3 (es) | 2011-01-26 | 2018-06-13 | Allergan, Inc. | Composición androgénica para el tratamiento de una afección oftálmica |
WO2012155062A1 (en) * | 2011-05-12 | 2012-11-15 | Foresight Biotherapeutics, Inc. | Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories |
US20140080765A1 (en) | 2011-05-20 | 2014-03-20 | Kowa Company, Ltd. | Novel metalloprotein and process for producing same, and prophylactic or therapeutic agent for corneal and conjunctival diseases comprising said metalloprotein |
EP2726081A4 (en) | 2011-06-29 | 2015-04-15 | Insite Vision Inc | METHOD FOR TREATING RECURRING MIBOMEDE DISEASE AND REDUCING THE FREQUENCY FROM THEIR RECURRENCE |
ITFI20120044A1 (it) | 2012-03-01 | 2013-09-02 | Biodue Spa | Formulazione ad uso oftalmico comprendente olio di jojoba. |
CN104254339B (zh) | 2012-04-16 | 2020-01-21 | 路博润高级材料公司 | 用于治疗和/或护理皮肤和/或粘膜的化合物和它们在化妆品组合物或药物组合物中的用途 |
WO2014078956A1 (en) | 2012-11-20 | 2014-05-30 | Revive Therapeutics Inc. | The use of bucillamine in the treatment of gout |
US9211397B2 (en) | 2012-12-19 | 2015-12-15 | Senju Usa, Inc. | Patch for treatment of eyelid disease containing clobetasol |
JP6351629B2 (ja) | 2013-01-24 | 2018-07-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 点眼用組成物 |
WO2015017316A2 (en) | 2013-08-01 | 2015-02-05 | Abbott Nicholas L | Methods and compositions for modifying mucous membranes |
WO2015022546A1 (en) | 2013-08-14 | 2015-02-19 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
WO2015169728A1 (en) | 2014-05-07 | 2015-11-12 | Croma-Pharma Gesellschaft M.B.H. | Aqueous ophthalmic solution and method for treating dry eye syndrome |
EP3151827A4 (en) | 2014-06-04 | 2018-01-24 | Tersus Pharmaceuticals, LLC | METHODS OF TREATING CHRONIC DRY EYE DISEASE USING C16:1n7 PALMITOLEATE AND DERIVATIVES THEREOF |
US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
JP2018533622A (ja) | 2015-09-28 | 2018-11-15 | アズーラ オフサルミックス エルティーディー. | マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤 |
CN105456287B (zh) | 2015-12-03 | 2017-06-30 | 大有药业扬州有限公司 | 二硫化硒超微粉体及其制备方法 |
KR102414557B1 (ko) | 2016-04-14 | 2022-06-28 | 아주라 오프탈믹스 엘티디 | 마이봄샘 기능 이상의 치료에 사용하기 위한 이황화셀레늄 조성물 |
MA44737A (fr) | 2016-04-19 | 2021-04-07 | Azura Ophthalmics Ltd | Compositions pour le traitement de troubles liés à l'hyperkératose |
-
2015
- 2015-06-05 US US14/732,622 patent/US9463201B2/en active Active
- 2015-10-16 CN CN202110190118.5A patent/CN112972682A/zh active Pending
- 2015-10-16 PT PT158520866T patent/PT3206497T/pt unknown
- 2015-10-16 PL PL15852086T patent/PL3206497T3/pl unknown
- 2015-10-16 EP EP20208119.6A patent/EP3831396A1/en active Pending
- 2015-10-16 MX MX2017005030A patent/MX2017005030A/es unknown
- 2015-10-16 KR KR1020217014908A patent/KR102350869B1/ko active IP Right Grant
- 2015-10-16 SI SI201531506T patent/SI3206497T1/sl unknown
- 2015-10-16 HU HUE15852086A patent/HUE053485T2/hu unknown
- 2015-10-16 BR BR112017007975A patent/BR112017007975A2/pt not_active Application Discontinuation
- 2015-10-16 JP JP2017520877A patent/JP6799532B2/ja active Active
- 2015-10-16 ES ES15852086T patent/ES2848102T3/es active Active
- 2015-10-16 LT LTEP15852086.6T patent/LT3206497T/lt unknown
- 2015-10-16 DK DK15852086.6T patent/DK3206497T3/da active
- 2015-10-16 WO PCT/IB2015/002164 patent/WO2016063130A1/en active Application Filing
- 2015-10-16 CN CN201580069536.1A patent/CN107105669B/zh active Active
- 2015-10-16 CA CA2964685A patent/CA2964685A1/en active Pending
- 2015-10-16 KR KR1020177013487A patent/KR102255726B1/ko active IP Right Grant
- 2015-10-16 EP EP15852086.6A patent/EP3206497B1/en active Active
- 2015-10-16 RS RS20210003A patent/RS61295B1/sr unknown
- 2015-10-16 AU AU2015334586A patent/AU2015334586B2/en active Active
- 2015-10-16 RU RU2017115563A patent/RU2730464C2/ru active
-
2016
- 2016-09-19 US US15/269,833 patent/US10034887B2/en active Active
-
2017
- 2017-04-13 IL IL251724A patent/IL251724B/en active IP Right Grant
- 2017-04-18 MX MX2021001439A patent/MX2021001439A/es unknown
-
2018
- 2018-06-26 US US16/019,253 patent/US10588915B2/en active Active
-
2019
- 2019-09-05 US US16/562,374 patent/US10772899B2/en active Active
-
2020
- 2020-03-03 AU AU2020201548A patent/AU2020201548A1/en not_active Abandoned
- 2020-06-05 JP JP2020098624A patent/JP2020169181A/ja active Pending
- 2020-07-02 US US16/919,749 patent/US11013749B2/en active Active
-
2021
- 2021-01-17 IL IL280209A patent/IL280209A/en unknown
- 2021-01-18 CY CY20211100035T patent/CY1123821T1/el unknown
- 2021-01-19 HR HRP20210085TT patent/HRP20210085T1/hr unknown
- 2021-04-21 US US17/236,258 patent/US11633410B2/en active Active
-
2023
- 2023-01-10 JP JP2023001954A patent/JP2023062705A/ja active Pending
- 2023-03-08 US US18/119,251 patent/US20230218642A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210085T1 (hr) | Pripravci i postupci za liječenje disfunkcije meibomske žlijezde | |
EA201990820A1 (ru) | Способы лечения митохондриальных и метаболических нарушений | |
WO2017178892A3 (en) | Selenium disulfide compositions for use in treating meibomian gland dysfunction | |
IL255203B (en) | Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders | |
BR112018015824A2 (pt) | composições para higiene pessoal | |
BR102016017090B8 (pt) | Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável | |
CL2017001488A1 (es) | Benzamidas sustituidas con 1,3–tiazol–2–ilo | |
HRP20210342T1 (hr) | Pripravci glikopeptida | |
MX2017010220A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
BR112016022159B8 (pt) | Pó e método para melhorar a aplicação tópica de um agente de benefício ácido | |
RS54584B1 (en) | 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE | |
DOP2015000303A (es) | Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por vía oral | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
BR112017000998A2 (pt) | composições, e uso da composição | |
BR112015019264A2 (pt) | composições farmacêuticas para o tratamento de helicobacter pylori | |
MX2016014411A (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. | |
BR112018012952A2 (pt) | composições para higiene pessoal | |
BR112018073924A2 (pt) | composições de gel à base de bactérias para aplicações tópicas e usos das mesmas | |
MA50670A (fr) | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose | |
CY1123360T1 (el) | Ενωσεις oi οποιες εχουν αντιοξειδωτικη δραση εναντι των ελευθερων ριζων και αντιφλεγμονωδη δραση, και αντιστοιχες φαρμακευτικες συνθεσεις για τη φροντιδα του δερματος | |
JP2016175884A5 (hr) | ||
EA201992521A1 (ru) | Наноэмульсии со стабилизированными в отношении цвета активными веществами | |
BR112018070064A2 (pt) | composições farmacêuticas estáveis para administração tópica e uso das mesmas | |
BR112017017685A2 (pt) | formulações farmacêuticas de inibidor de c1 esterase | |
BR112016023737A2 (pt) | ?composição agrícola, e, método de condicionamento de água? |